InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Bazemore Todd, Chief Operating Officer. Director active across 3 companies, notably Kala Pharmaceuticals, Inc.. In total, 16 disclosures have been published. Split: 0 buy · 10 sells. Total volume traded: €132k. Activity tracked since 28 June 2021. The latest transaction was filed on 22 October 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Bazemore Todd
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
47,768 shares@ US$0.8337.2% of flowCommon StockSEC:0001605767-25-000004:0
4,058 shares@ US$4.0124.3% of flowCommon StockSEC:0001415889-25-018319:0
3,390 shares@ US$3.7425.5% of flowCommon StockSEC:0001415889-25-015679:0
10,100 shares0Common StockSEC:0001415889-25-001062:0
4,653 shares@ US$4.7563.8% of flowCommon StockSEC:0001415889-24-018377:0
2,093 shares@ US$6.0936.2% of flowCommon StockSEC:0001415889-24-015226:0
6,500 shares0Common StockSEC:0001415889-24-000766:0
48,698 shares0Common StockSEC:0001415889-23-010283:0
21,158 sharesCommon StockSEC:0001415889-23-009134:0
12,800 shares0Common StockSEC:0001415889-23-000637:0
214 shares@ US$6.511.8% of flowCommon StockSEC:0001415889-22-010881:0
3,092 shares@ US$0.370.0070% mcap1.4% of flowCommon StockSEC:0001415889-22-007060:0
3,454 shares@ US$1.309.9% of flowCommon StockSEC:0001415889-22-000403:0
12,544 shares@ US$1.8048.7% of flowCommon StockSEC:0001415889-21-005011:0
2,911 shares@ US$5.7735.2% of flowCommon StockSEC:0001415889-21-003257:0
13,750 sharesCommon StockSEC:0000908662-16-000427:0
16 of 16 declarations
About Bazemore Todd
Bazemore Todd is Chief Operating Officer. He has 16 filings in total, and the 16 sampled filings, from 2016-01-22 to 2025-10-24, show only sales for a total of EUR 131745, with filings at KALA BIO, Inc. and Kala Pharmaceuticals, Inc.
